Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole Dose-Response Biomarker Study in PTSD
NCT02934932Phase 2Terminated
- Sponsor
- Duke University
- Start
- Apr 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brexpiprazole in post-traumatic stress disorder (PTSD) (3 arms), sponsored by Duke University. Primary endpoint: Change in Resting Pupil Diameter at 6 weeks. Started Apr 2017; status: terminated.
02
Drugs
brexpiprazole
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT02934932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934932.